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W hat is the purview of the institutional animal care and use committee (IACUC) in reviewing stem cell research?
The intent of US federal laws mandating IACUC review 
of animal-related activities was to satisfy contemporary so-
cioethical concerns by introducing deliberations about ethics 
and animal welfare into the research process when animals 
are used. These laws and the system they chartered have 
worked well for the most part in providing opportunities for 
consideration of animal welfare as a vital part of animal re-
search. As a result, investigators today are far less naïve 
about the ethical issues raised by research on animals and 
typically more sympathetic about the need for such consid-
eration. As evidence of this growing awareness, the literature 
on and use of analgesia and other modalities for controlling 
pain (and, more recently, distress) in research protocols have 
grown exponentially, and the issue of environmental enrich-
ment for animals used in research continues to challenge the 
research community to consider animal husbandry beyond 
uniformity in animal care and the provision of a clean cage 
with food and water. 
Good Ethics and Bad Ethics
Anyone professionally involved in animal experimentation 
knows that IACUC oversight has had a signifi cant impact on 
how research is performed. Perhaps less obvious is the role 
of the IACUC in helping to educate the general public about 
issues that some people believe are matters of ethics but that 
in fact are not. 
Questions about ethics and morality arise most often 
across the range of biotechnological investigations, in a phe-
nomenon that has been dubbed a “Gresham’s Law of ethics” 
(Rollin 1995). Gresham’s Law in economics states that “bad 
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money drives good money out of circulation.” Thus, for ex-
ample, in post–World War I Germany, when paper deutsche-
marks were essentially valueless (vast amounts of currency 
were required to buy a loaf of bread), citizens capitalized on 
the opportunity to pay off large debts (such as mortgages) 
with the valueless currency rather than with gold. With re-
spect to the current topic, Gresham’s Law of ethics refers to 
dicta lacking genuine ethical import. Such dicta proliferated 
in the absence of the research community’s articulation of 
the genuine ethical issues that arose in the wake of genetic 
engineering or cloning; examples of these nonethical pro-
nouncements include “cloning violates God’s will” and “ge-
netic engineering desacralizes nature” or “blurs species 
boundaries” or “does not show proper respect for the gift of 
life.” Since such assertions lack clear meaning, they cannot 
be dispatched by simple responses. How, for example, does 
one determine the truth of the claim that “cloning violates 
God’s will”?
Such infl ammatory claims unfortunately play well with a 
scientifi cally illiterate public. That public sees species as fi xed 
and immutable “natural” kinds and is upset by the rapidity of 
change in organisms that can be effected by biotechnology, as 
opposed to the slow change traditionally created by natural 
and artifi cial selection. Biotechnology, perhaps more than any 
other area of investigation, tends to elicit “Gresham’s Law of 
ethics” because it is seen as tinkering with “the very nature of 
life.” It may thus raise questions for some IACUC members 
that go beyond genuine ethical issues.
However strongly felt, matters that allegedly violate reli-
gious principles or metaphysical perspectives should not rise 
to the level of ethical issues in a secular society that strives 
to separate church and state, as has been discussed in detail 
regarding stem cell technology (Rollin 2006). Therefore, we 
argue that the general issue of the “ethicality” of stem cell 
use, versus specifi c implications for animal welfare en-
gendered by animal model–based studies, is beyond the 
purview of the IACUC insofar as that issue is largely theo-
logically based. 
Politicians and political activists have heatedly debated 
the morality of stem cell use, resulting in a spate of regula-
tions that may concern the IACUC but do not directly re-
quire its oversight. A well-known example is the signifi cant 
limitation imposed by recent administrations restricting the 
use of fetal tissue for stem cell development. Regardless of 
whether this decision is logical based on secular American 
societal ethics, it remains a major concern in some quarters. 
Volume 51, Number 1  2010 83
Thus the IACUC, perhaps in partnership with the institu-
tional review board (IRB) that reviews research on humans 
or internal committees specialized in reviewing research 
with human embryonic stem cells, must ensure that research-
ers scrupulously adhere to all regulations regarding sources 
of fetal material. However, it is outside the scope of the IA-
CUC’s charge to debate the “morality” of stem cell research 
or to require investigators to address the nuances of public 
debate surrounding the origin and sanctity of life if they pro-
pose to use stem cells to address a scientifi c question using 
animal models.
Chimeras and Clones
A signifi cant and problematic spurious issue will arise when 
human stem cells, whether derived from fetal tissue or not, 
are inserted into an animal, creating a chimeric xenograft. 
Although this process is arguably similar to the use of ani-
mals to grow human tumors, tissues, or proteins—routinely 
practiced in other scientifi c investigations—the specter of 
intermixing species genotypes using primordial germ cells 
would predictably be more likely to raise public concerns. 
Chimeric entities are, after all, the stuff of nightmares—
gorgons, werewolves, mermaids—and the possibility of cre-
ating them raises fear of “the Frankenstein syndrome” 
(Rollin 1995). Such research can elicit cries of “mixing 
humans and animals,” “debasing human dignity,” “failing to 
respect human nature,” and variations on such themes. This 
sort of response is, as mentioned, unanswerable in rational 
terms, but nonetheless needs to be addressed and the results 
of the discussion documented and disseminated. 
The use of primordial germ cells to create “clones” of an 
animal also raises concerns in certain sectors of society. While 
the existence of identical twins might indicate that this phe-
nomenon occurs naturally, and in fact companies have been 
founded to preserve genetic material from beloved pets, the 
creation of Dolly the cloned sheep sparked much discussion 
about the “ethics” of cloning using tissue from adult animals. 
Public concern was enfl amed by the specter of persons creat-
ing genetically identical humans to serve some sinister pur-
pose, but this is the hyperbole of disturbing science fi ction. 
Again, the debate regarding these issues is beyond the 
purview of the IACUC’s regulatory authority. However, since 
much research is done with public money and with the per-
mission of the public, scientists cannot be contemptuous or 
dismissive of public opinion. While not required by statutory 
authority, the IACUC minutes might refl ect discussions of 
societal concerns, particularly if these involve “hot button” 
issues such as those described here, in the hope of clarifying 
the difference between real and spurious ethical issues. 
Practical Guidelines
Reasonable guidelines (adapted from NRC 2005) suggest 
that protocols incorporating the use of human embryonic 
stem (hES) cells address the following questions:
•  Are hES cells required, or can cells from other primates 
or animals or nonembryonic human tissue be used?
•  Has suffi cient animal work preceded the proposed work 
involving hES cells?
• Might the cell transfer result in the animal’s acquiring 
characteristics that are valued as distinctly human?
•  If hES cells are to be transferred into an animal embryo 
or fetus, have studies (for example, with ES cells from 
other species or interspecies chimeras) suggested that 
the resulting creature would exhibit human characteris-
tics that would be allegedly ethically unacceptable to 
fi nd in an animal?
•  If visible human-like characteristics might arise, have all 
those involved in these experiments, including animal 
care staff, been informed and educated about this?
Several of these points may have relevance for IACUC or 
animal care program oversight of hES experimentation, and 
thus are provided here as a point of reference. 
Issues Relevant to IACUC Review 
The ethical issues associated with stem cell research in the 
context of experimental studies using animals concern pos-
sible harm, pain, distress, and disease that may accompany 
the animal manipulation. For example, standard approaches 
to transplanting animal stem cells may require induced or 
genetically engineered immunosuppression, creating the 
potential for signifi cant morbidity and requiring intensive 
monitoring and pharmacological management. The IACUC 
therefore must ensure that the investigator has devoted 
adequate resources to the monitoring and management of 
resulting opportunistic infections or tissue damage related to 
cytotoxins or radiotherapy, for example. 
Similarly, stem cell therapies are being targeted to treat 
diseases that are often severe and debilitating (e.g., diabetes 
mellitus, arthritis, and neurodegenerative disorders, as dis-
cussed in this issue; Joers and Emborg 2010; Song et al. 
2010). Animal model systems designed to evaluate stem cell 
therapy interventions for such diseases must replicate the 
disease states, which are likely to cause pain and distress in 
control animals or in animals for which the therapies are inef-
fective. Because there are often no modalities for controlling 
the pain and distress occasioned by these diseases even in 
human patients, the IACUC must consider and weigh the 
potential for detection and mitigation of pain and distress in 
these animals, and must carefully evaluate experimental end-
points for these studies. In some cases—for example, when 
researchers wish to study the full course of the disease—early 
endpoints are not an option to curtail suffering (Rollin 1995).
Considerations such as immunosuppression and chronic 
disease expression are not unique or specifi c to stem cell 
therapy and have been reviewed elsewhere (e.g., NRC 2008, 
2009). Investigators and animal care staff should 
•  be aware of potential complications of induced disease, 
immunosuppression, and other conditions that may result 
in studies involving the use of stem cells in animals, 
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•  be able to recognize symptoms that demonstrate animal 
pain and distress, 
•  take actions to symptomatically minimize distress asso-
ciated with sequelae (e.g., provide ready access to food 
and water if ambulation is impaired, provide analgesics 
if possible, maintain hydration), and 
•  establish well-defi ned observation frequencies and end-
points for euthanasia in response to anticipated adverse 
effects.
Conclusion
While stem cell experiments raise concerns about the do-
minion of humans in manipulating animals at the level of the 
genome, most of the issues debated in the press and political 
arenas about stem cell experiments do not fall under IACUC 
regulatory authority. It may be prudent to discuss such issues 
when they are presented during protocol review as a matter 
of public responsibility, but the primary IACUC issues raised 
by animal experimentation involving stem cells recapitulate 
the common issues of animal welfare attendant upon the in-
duction of immunosuppression or chronic diseases.
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